Researchers at McGill University have challenged the conventional understanding of dopamine's function in movement, suggesting it acts more like engine oil than a gas pedal. This discovery, published in Nature Neuroscience, could simplify treatments for Parkinson's disease by focusing on maintaining steady dopamine levels. The findings stem from experiments showing that dopamine enables movement without directly controlling its speed or force.
A team led by Nicolas Tritsch, an assistant professor in McGill University's Department of Psychiatry and a researcher at the Douglas Research Centre, conducted experiments that upend long-held beliefs about dopamine. Traditionally, scientists thought dopamine acted as a direct regulator of motor vigor—the speed and strength of movements—through brief bursts during activity. However, the study reveals that dopamine primarily provides the foundational conditions for movement to occur, rather than fine-tuning its intensity moment by moment.
In the research, scientists monitored brain activity in mice as they pressed a weighted lever. Using a light-based technique, they activated or inhibited dopamine-producing cells precisely during these actions. Surprisingly, these manipulations had no effect on how fast or forcefully the mice moved, contradicting the idea that rapid dopamine fluctuations drive vigor.
"Our findings suggest we should rethink dopamine's role in movement," Tritsch stated. "Restoring dopamine to a normal level may be enough to improve movement. That could simplify how we think about Parkinson's treatment."
Parkinson's disease affects over 110,000 Canadians, with numbers projected to more than double by 2050 due to an aging population. The condition arises from the gradual loss of dopamine-producing brain cells, causing symptoms like slowed movement, tremors, and balance issues. The standard treatment, levodopa, replenishes dopamine and alleviates these problems, but its exact mechanism was unclear.
The study clarifies that levodopa works by elevating baseline dopamine levels in the brain, not by recreating the short bursts associated with motion. This insight, detailed in the paper "Subsecond dopamine fluctuations do not specify the vigor of ongoing actions" by Haixin Liu, Riccardo Melani, and colleagues, was funded by the Canada First Research Excellence Fund through McGill's Healthy Brains, Healthy Lives initiative and the Fonds de Recherche du Québec.
These results may inspire more targeted therapies, potentially reducing side effects from drugs like dopamine receptor agonists that broadly influence the brain. By emphasizing stable dopamine maintenance, future treatments could offer safer options for Parkinson's patients.
